{"id":"aripiprazole-adt","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:10:14.321636","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, stabilizing dopaminergic neurotransmission and reducing psychotic symptoms. The combination with ADT addresses both the psychiatric manifestations and hormonal aspects of the condition being treated, likely targeting patients with prostate cancer or related conditions who experience treatment-related psychiatric side effects.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist combined with an androgen deprivation therapy (ADT) agent to treat psychiatric symptoms in patients undergoing hormone therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:25.441Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psychiatric symptoms in patients receiving androgen deprivation therapy for prostate cancer or related conditions"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT00105196","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Major Depressive Disorder","enrollment":349}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2012 May","pmid":"22466058","title":"Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.","journal":"International clinical psychopharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify"],"phase":"phase_3","status":"active","brandName":"Aripiprazole+ ADT","genericName":"Aripiprazole+ ADT","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist of the dopamine D2 receptor, classified as a small molecule. Aripiprazole is being studied as an adjunct to antidepressant therapy (ADT) for the treatment of Major Depressive Disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}